Colan Totte.Co.,Ltd. (7792) AI Stock Analysis

Colan Totte.Co.,Ltd.

(TSE/TYO:7792)

Select Model

Rating:82Outperform

Price Target:JPY 1,690.00▲(18.93% Upside)

Action:reiterated

Date:08/05/26

The stock scores 82, reflecting strong financial performance, positive technical trends, and attractive valuation. The company's robust profitability, pristine balance sheet, and accelerating revenue growth are key strengths. While cash flow conversion lags net income, the low P/E and solid dividend yield provide a margin of safety. Technical indicators show bullish momentum with price above moving averages and positive MACD, though Stochastic is nearing overbought levels. Overall, the stock presents a favorable investment profile.

Positive Factors

High profit marginsSustained high gross (67.33%) and net (19.20%) margins indicate durable pricing power and an efficient cost structure in the medical-devices business. These margins create long-term cash flow cushion, support reinvestment in R&D, and give flexibility to sustain profits through industry cycles.

Negative Factors

Free cash flow volatilityHistorical volatility in free cash flow undermines predictability for funding capex, R&D and shareholder returns. Even with strong conversion ratios on average, intermittent FCF declines can force management to curtail investments or dividends, limiting strategic flexibility over the medium term.

Colan Totte.Co.,Ltd. (7792) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 13.08B
Dividend Yield: 3.48%
Average Volume (3M): 14.24K
Price to Earnings (P/E): 9.2
Beta (1Y): 0.53
Revenue Growth: 33.43%
EPS Growth: 12.57%
Country: Japan
Employees: 104
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Colan Totte.Co.,Ltd. Business Overview & Revenue Model

Company Description

Colan Totte Co., Ltd., established in Osaka, Japan, in 1997, operates as an international firm specializing in the development and global distribution of therapeutic devices under its proprietary Colantotte brand. The company's diverse product portfo...

How the Company Makes Money

null

Colan Totte.Co.,Ltd. Financial Statement Overview

Summary

Strong profitability with high margins and accelerating revenue growth; exceptional balance sheet with minimal debt and high ROE; cash flow improved but conversion ratios lag net income, indicating some inefficiencies. Overall financial health is strong.

Income Statement

85Very Positive

Balance Sheet

95Very Positive

Cash Flow

70Positive

Financial statement breakdown
Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	8.02B	6.92B	5.94B	5.41B	4.66B	3.71B
Gross Profit	5.46B	4.66B	3.97B	3.45B	3.04B	2.46B
EBITDA	2.06B	1.90B	1.57B	1.10B	1.02B	691.13M
Net Income	1.35B	1.33B	1.02B	645.02M	610.45M	420.50M
Balance Sheet
Total Assets	7.18B	6.74B	5.43B	4.91B	4.13B	3.62B
Cash, Cash Equivalents and Short-Term Investments	2.11B	2.18B	1.76B	1.79B	1.34B	1.55B
Total Debt	8.05M	12.90M	8.69M	1.27M	270.48M	439.84M
Total Liabilities	1.62B	1.57B	1.32B	1.64B	1.38B	1.38B
Stockholders Equity	5.55B	5.17B	4.11B	3.27B	2.75B	2.24B
Cash Flow
Free Cash Flow	1.06B	728.70M	357.26M	867.34M	75.48M	597.37M
Operating Cash Flow	1.48B	998.35M	883.77M	955.70M	148.09M	637.27M
Investing Cash Flow	-471.40M	-303.40M	-736.91M	-83.80M	-80.38M	-51.45M
Financing Cash Flow	-654.18M	-272.18M	-180.15M	-410.10M	-274.23M	452.40M

Colan Totte.Co.,Ltd. Technical Analysis

Technical Analysis SentimentNeutral

Last Price1421.00

Price Trends

50DMA1444.04Negative

100DMA1422.21Positive

200DMA1413.08Positive

Market Momentum

MACD-1.19Positive

RSI43.42Neutral

STOCH12.27Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7792, the sentiment is Neutral. The current price of 1421.00 is below the 20-day moving average (MA) of 1464.70, below the 50-day MA of 1444.04, and above the 200-day MA of 1413.08, indicating a neutral trend. The MACD of -1.19 indicates Positive momentum. The RSI at 43.42 is Neutral, neither overbought nor oversold. The STOCH value of 12.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7792.

Colan Totte.Co.,Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

JP:7792 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:7792	82Outperform	JPY 13.12B	9.25	―	3.48%	33.43%	12.57%
JP:5187	70Outperform	JPY 10.13B	16.49	―	4.31%	5.20%	-17.92%
JP:6849	61Neutral	JPY 265.01B	19.32	―	1.98%	1.43%	1.86%
JP:6523	58Neutral	JPY 180.17B	19.53	5.76%	2.97%	3.04%	-19.26%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
JP:4549	50Neutral	JPY 76.06B	41.05	―	2.51%	3.92%	-52.01%
JP:7600	47Neutral	JPY 15.22B	-69.06	―	2.94%	-6.64%	67.08%

* General Sector Average

Performance Comparison

JP:7792 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:7792	Colan Totte.Co.,Ltd.	1438.00	3.13	0.22%
JP:6523	PHC Holdings Corp.	1415.00	438.88	44.96%
JP:4549	Eiken Chemical Co., Ltd.	2307.00	3.99	0.17%
JP:5187	Create Medic Co., Ltd.	1114.00	129.57	13.16%
JP:6849	Nihon Kohden Corporation	1616.50	-129.90	-7.44%
JP:7600	Japan Medical Dynamic Marketing, Inc.	578.00	115.01	24.84%

Colan Totte.Co.,Ltd. Corporate Events

Colan Totte Lifts Sales, Guidance and Dividend on Strong First‑Half Earnings

May 8, 2026

Colan Totte reported robust non‑consolidated results for the six months ended March 31, 2026, with net sales rising 34.1% year on year to ¥4.33 billion and operating profit up 18.2% to ¥1.12 billion, while profit edged up 3.3% to &#16...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 04, 2026

Colan Totte.Co.,Ltd. AI Stock Analysis